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Abstract In previous studies, low blood levels of n-3
fatty acids (FA) have been associated with increased risk of
cardiac death, and the omega-3 index (red blood cell
(RBC) eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) expressed as weight percentage of total FA)
has recently been proposed as a new risk factor for death
from coronary artery disease, especially following sudden
cardiac arrest (SCA). As blood samples often haven been
harvested after the event, the aim of our study was to
evaluate the stability of RBC fatty acids following SCA.
The total FA proﬁle, including the omega-3 index, was
measured three times during the ﬁrst 48 h in 25 survivors
of out-of-hospital cardiac arrest (OHCA), in 15 patients
with a myocardial infarction (MI) without SCA and in 5
healthy subjects. We could not demonstrate signiﬁcant
changes in the FA measurements in any of the groups, this
also applied to the omega-6/omega-3 ratio and the ara-
chidonic acid (AA)/EPA ratio. Furthermore, we compared
the omega-3 index in 14 OHCA-patients suffering their
ﬁrst MI with that of 185 ﬁrst-time MI-patients without
SCA; mean values being 4.59% and 6.48%, respectively
(p = 0.002). In a multivariate logistic regression analysis,
a 1% increase of the omega-3 index was associated with a
58% (95% CI: 0.25–0.76%) reduction in risk of ventricular
ﬁbrillation (VF). In conclusion, the omega-3 index
remained stable after an event of SCA and predicted the
risk of VF.
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The ﬁrst clinical evidence of a possible protective effect of
n-3 fatty acids (FA) against sudden cardiac death (SCD)
came from the publication of the GISSI-Prevenzione trial
in 1999 [1]. In this study, supplementation with 1 g/day of
n-3 FA following a myocardial infarction (MI) resulted in a
45% reduction of sudden deaths during 3.5 years of follow-
up. This ﬁnding has been supported by the demonstration
of low levels of blood n-3 FA in patients suffering SCD
[2, 3] or a fatal cardiac event [4]. In addition, our research
group has recently presented evidence for an increased risk
of ventricular ﬁbrillation (VF) during the acute ischemic
phase of an MI in patients with low levels of cellular n-3
FA [5]. In our study, as well as in a previous investigation
[3], blood samples were harvested after the episode of
sudden cardiac arrest (SCA). To obtain a reliable result
with this method, we have to assume that the blood com-
position of FA remains stable following the event, or else
we need to correct for changes induced by the event itself
in selected case–controls.
Previous studies have demonstrated signiﬁcant changes
in FA composition of serum [6] and plasma lipids [7] in the
early stage of an MI. Recently, the red blood cell (RBC) FA
composition has been found to reﬂect the cardiac omega-3
content [8, 9]. Even though stable in rats for 24 h after the
induction of an MI [7], the only evaluation of post-MI RBC
FA in humans demonstrated a statistically signiﬁcant
change in the investigated FA during a 7 day period [10].
As most episodes of cardiac arrest appear during the early
course of an MI, these ﬁndings are of interest when
assessing the FA proﬁle of SCD/SCA-patients.
In patients with SCA, the event itself, as well as the
resuscitation, might potentially affect the measurements.
Stress-induced or injected adrenalin can activate phos-
pholipases, releasing FA from cell membrane phospholip-
ids leading to falsely low post-resuscitation measurements.
The only evaluation of this question has so far been per-
formed in animal studies, in which no signiﬁcant effect of
adrenalin on the FA composition in RBC [3] or serum
lipids [11] has been observed. FA stability after an episode
of cardiac arrest has previously not been reported in
humans, and this was the primary aim of our study.
Based on the proposed post-MI changes in FA, we
wanted to compare the time-related proﬁle of RBC FA in
SCA-patients with that of MI-patients without a cardiac
arrest. We also wanted to evaluate whether the level of
RBC eicosapentaenoic acid (EPA) ? docosahexaenoic
acid (DHA) (the omega-3 index) might be related to VF, as
previously demonstrated in another group of SCA patients
[5].
Materials and Methods
Study Subjects and Design
This study was performed at Stavanger University Hospi-
tal, Stavanger, Norway. The inclusion criteria were; age
[18 years and out-of-hospital cardiac arrest (OHCA) of
assumed cardiac origin. Patients with permanent return of
spontaneous circulation (ROSC) had 6 mL of EDTA-
blood drawn on hospital admission. Further blood sampling
was repeated after 8–12 h and after 24–48 h. At this point,
most patients were on a respirator at the intensive care unit,
and blood samples were collected from an already estab-
lished arterial crane. For the few patients who woke up
immediately after resuscitation, blood sampling was per-
formed as part of the hospital’s routine. Echocardiography
was performed shortly after admission for the evaluation of
the ejection fraction (EF). Survivors gave written informed
consent before discharge. If the patient stayed unconscious
until death, the family was asked for consent on the
patient’s behalf.
From February 2007 until June 2009, blood samples for
evaluation of RBC FA were collected from 25 patients with
documented VF. Patients were divided into three groups
based on the mechanism of their ventricular arrhythmia;
(1) SCA without a present MI, (2) SCA with a ﬁrst-time MI
and (3) SCA with recurrent MI. The presence or absence of
an MI was determined from the release pattern of troponin-
T (TnT), using ST-segment analysis of the electrocardio-
gram (ECG) for the deﬁnition of ST-elevation MI (STEMI)
or non-ST-elevation MI (NSTEMI). For one case, there
were only two in-hospital samples available, and this
patient was only included in the analysis of risk.
For the evaluation of MI related FA changes, 15 subjects
with an acute MI (AMI) without SCA were recruited. In
this group, MI was deﬁned by a maximal TnT[0.03 lg/L
and a typical release pattern. EDTA-blood from most of
these patients was collected as part of the hospital’s routine
at admission or at coronary angiography and during the
subsequent 48 h, employing the same time points as
described for the SCA-patients. After collection of blood
and baseline characteristics, the identity of these patients
was destroyed and all samples treated anonymously. The
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123selection of the MI-patients was not sufﬁciently random for
them to serve as controls for the assessment of risk.
To rule out a biological variation of the FA proﬁle, we
also analyzed a subsequent set of three blood samples in 5
healthy subjects, 3 men and 2 women, with an age of
34–72 years. The ﬁrst and last (after 24 h) blood samples
were drawn after an overnight fast, the second sample was
in the fed state 8–12 h after the ﬁrst one.
For risk evaluation, we compared the admission omega-
3 index in the SCA-patients with ﬁrst-time MI with our
previous control-population of 185 ﬁrst-time MI patients
from the Risk factors in Acute Coronary Syndrome
(RACS, ClinicalTrials.gov identiﬁer: NCT00521976) study
[5]). In that study, patients with chest pain or otherwise
suspected acute coronary syndrome (ACS) were included
at the same hospital from November 2002 until September
2003. Blood samples for the analysis of the omega-3 index
were harvested immediately after admission, without sub-
sequent sampling during hospitalization. Controls were
selected based on the absence of VF or sustained ventric-
ular tachycardia (VT) for at least 30 days of follow-up.
The present study was approved by the Regional Board
of Research Ethics and the Norwegian Health Authorities
and conducted in accordance with the Helsinki Declaration
of 1975, as revised in 1983.
Laboratory Methods
Storage of blood samples prior to preparation was allowed
for 24 h at room-temperature and 48 h in a refrigerator.
RBC for analysis of FA were prepared from EDTA-blood
after centrifugation at 2,500g for 10 min in room temper-
ature. Plasma was extracted and the buffy coat discarded,
after which sedimented RBC were washed twice with
phosphate buffered saline (PBS), followed each time by
centrifugation at 2,500g for 3 min. All samples were stored
at –70 C until extraction of FA could be performed. At
this temperature, the composition of RBC FA has been
demonstrated to remain stable for at least 4 years [12].
For the FA analysis a 50-lL sample of thawed packed
RBC was placed on a ﬁlter paper disc (Whatman grade 1,
3.0 cm diameter) that had been pre-treated with butylated
hydroxytoluene (50 mg/L) according to Marangoni et al.
[13]. Dried blood spots were shipped to the US and the FA
composition analyzed in the laboratory of W. S. Harris by
ﬂame ionization gas chromatography (GC9A, Shimadazu
Corporation, Columbia, MD, USA), as previously descri-
bed [5]. FA in dried RBC-samples remain stable during
storage and shipment in cooled conditions for at least
1 week, as previously described [14]. We have also shown
that dried RBC-samples can be stored at -70 C for
1.5 years with no reduction in the omega-3 index (n = 22)
(unpublished data). The coefﬁcient of variation (CV) for
the omega-3 index was 6%. Laboratory personnel per-
forming the analyses were blinded with respect to clinical
events.
Statistical Analyses
Characteristics of cases and controls are given as
means ± standard deviations (SD) for normally distributed
variables and as medians with interquartile range (25th–
75th percentile) when the assumption of normality was
violated. Differences between groups at baseline were
tested by the Mann–Whitney U Test and the Kruskal–
Wallis Test for non-normally distributed variables with the
independent samples t test and the one-way between group
analysis of variance (ANOVA) as the parametric alterna-
tive. Categorical variables were evaluated using the Chi-
square test, or in the case of few expected observations, the
p value was derived from Fisher’s exact probability test.
The sample sizes of the subgroups of SCA-patients were,
however, too small to test for differences in inter-group
frequencies.
For the evaluation of FA stability following an event of
SCA and/or AMI we used one-way repeated measures
ANOVA to compare the omega-3 index and individual FA
at admission, after 8–12 h and after 24–48 h in the four
different groups of patients; (1) SCA without an AMI
(n = 6), (2) SCA with an AMI (both ﬁrst and recurrent)
(n = 18), (3) AMI without SCA (n = 15) and (4) healthy
subjects (n = 5). The analysis was performed for each
group with time as the only within-subject factor at three
levels. The Mauchly’s test of sphericity was used to check
that the correlations and variances of the observations
remained constant at all time points. The within-subject
CV was calculated from the mean and SD of the three
subsequent omega-3 index measurements, according to the
method described by Harris and Thomas [15].
To evaluate the association between the omega-3 index
and risk of VF we performed logistic regression analyses
adjusting for age and sex. In addition, high-sensitivity
C-reactive protein (hsCRP), EF and previous angina pec-
toris were included as potential confounders in a backward
elimination procedure, and stayed in the ﬁnal model if they
were signiﬁcant in the ﬁrst step. Based on the existing
knowledge of STEMI and anterior location as potential risk
factors for VF during the course of an AMI [16, 17], we
performed separate analyses for STEMI-patients only and
for patients with anterior location of their infarction. We
chose not to include maximal TnT as a measure of infarct
size due to the possibility of this parameter being differ-
entially affected by the mechanical manipulation of the
heart, by coronary hypoperfusion during resuscitation [18,
19] as well as by later percutaneous coronary intervention
(PCI) therapy [20]. The Odds Ratio (OR) for VF is
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123presented with 95% conﬁdence interval (CI). The statistical
analyses were performed with the statistical package SPSS
version 17.0, with p values derived from the logistic
regressions using the Wald chi-square test. All tests were
2-sided with a signiﬁcance level of 5%.
Results
Characteristics of SCA-Patients
Out of the 25 patients admitted after an event of OHCA, 19
experienced their VF during the initial course of an AMI.
The remaining 6 patients had no evidence of a present MI
and their arrhythmia was classiﬁed as primary VF with the
need for an implantable cardioverter deﬁbrillator (ICD)
prior to discharge. Patient characteristics for the different
SCA-groups are given in Table 1.
Fourteen out of the 19 AMI-patients, 12 men and 2
women, experienced their ﬁrst MI. These patients were
relatively young (median age 52.5 years, range 41–78 years)
and had a predominance of STEMI located to the anterior
wall of the heart and mainly one-vessel disease evaluated by
coronary angiography (Table 1). Retrospectively, 3 patients
had evidence of pre-infarction angina, but none of them had
received any treatment for this condition.
Characteristics of Control Subjects
The characteristics of the 185 control subjects (134 men
and 51 women) are presented in Table 2. As compared to
the group of SCA-patients with ﬁrst-time MI they were
signiﬁcantly older, had a higher frequency of NSTEMI at
admission, and at baseline hsCRP was signiﬁcantly higher
and s-glucose signiﬁcantly lower. For the remaining base-
line characteristics, including infarct location, previous
history, presence of risk factors, use of medication, EF and
degree of coronary artery disease (CAD), there were no
statistically signiﬁcant differences among the two groups.
Serial Measurements of Individual FA
and the Omega-3 Index
A plot of the means of the omega-3 index with 95% CI in
SCA patients with and without an AMI, in AMI-patients
without SCA and in healthy subjects is presented in Fig. 1.
Among patients with SCA, mean time from event to ﬁrst
sample was 1.3 ± 0.6 h. The time from admission until
ﬁrst, second and third sample was 0.5 ± 0.4, 11.1 ± 2.3
and 39.3 ± 6.0 h, respectively. After removing from the
analysis one patient with chest pain for at least 74 h before
the occurrence of cardiac arrest, patients with SCA during
the course of their AMI had a mean duration of symptoms
of 3.3 ± 5.7 h (range 0.6–21.0 h) at the time of the ﬁrst
sample. For AMI-patients without SCA, time from symp-
tom onset until ﬁrst sample was 3.4 ± 2.5 h (range
0.8–9.7 h) and from admission to subsequent sampling
0.3 ± 0.4, 10.2 ± 3.1 and 35.6 ± 6.8 h, respectively.
Healthy subjects had samples taken at time 0, after
8.1 ± 0.1 and 23.4 ± 0.4 h. The repeated measures
ANOVA (sphericity assumed) showed no statistically sig-
niﬁcant time-dependent effect on the omega-3 index in any
of the groups. The within-subject CV differed from 16.7%
in SCA-patients with an AMI to 10.4% in SCA-patients
with no AMI. The corresponding values for AMI-patients
without SCA and for healthy subjects were 11.7 and
12.9%, respectively.
Similar comparisons were performed for the individual
FA. As shown in Table 3 the FA proﬁle remained stable
irrespective of sampling time in each subject group.
Accordingly, the ratio between the omega-6 and omega-3
FA was also found to be stable, including the arachidonic
acid (AA) to EPA ratio.
Omega-3 Index and Risk of VF
The mean omega-3 index among SCA-patients with ﬁrst-
time AMI was 4.59% as compared to 6.48% in controls. In
the main logistic regression analysis age, sex, hsCRP and
EF were included as covariates, 12 cases and 177 controls
were enrolled based on available measurements. The
omega-3 index turned out to be a highly signiﬁcant pre-
dictor of VF during the course of a ﬁrst-time AMI with an
OR of 0.42 (95% CI; 0.24–0.75, p = 0.003). Of the other
covariates included in the analysis, only EF (OR 0.94, 95%
CI: 0.89–0.99) and hsCRP (OR 0.61, 95% CI: 0.39–0.95)
contributed to the risk of VF.
When restricting the analysis to patients admitted with
STEMI and to those with anterior location of their infarc-
tion, the omega-3 index still remained an independent
predictor of VF with an OR of 0.53 (95% CI: 0.29–0.96),
p = 0.037, in STEMI-patients (n = 91) and 0.50 (95% CI:
0.27–0.93), p = 0.028, among those with anterior infarc-
tions (n = 92) (Fig. 2).
Discussion
We have demonstrated that the RBC FA, including the
omega-3 index, remained stable after SCA and during the
post-MI period. In healthy subjects, we have also ruled out
any signiﬁcant biological variability, largely conﬁrming
previous observations on reproducibility over time [15].
There has been diverging results in previous studies
regarding the effect of an AMI on FA composition of
phospholipids [6, 7, 10]. Our ﬁndings are consistent with
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Men 12 (86%) 5 (100%) 5 (83%) nd
Women 2 (14%) 0 1 (17%)
Age (median, years) 52.5 (46.8–59.5) 68.0 (58.0–77.5) 73.5 (62.5–81.5) 0.006
BMI (mean ± SD, kg/m
2) 26.6 ± 3.9
b 26.4 ± 3.3
c 26.9 ± 4.3 0.017
Symptoms prior to SCA
Chest pain 10 (71%) 3 (60%) 0 nd
Dyspnea 0 0 1 (17%)
Asymptomatic 0 2 (40%) 4 (67%)
Unknown 4 (29%) 0 1 (17%)
ECG ﬁndings
STEMI 11 (79%) 3 (60%) 0 nd
NSTEMI 3 (21%) 2 (40%) 0
Infarct location
Anterior wall 10 (71%) 3 (60%) 0 nd
Inferior wall 3 (21%) 1 (20%) 0
Lateral wall 1 (7%) 1 (20%) 0
TnT max (median, lg/L) 4.55 (1.21–6.99) 4.53 (2.61–11.99) 0.16 (0.04–0.74) 0.005
Ejection fraction (median, %) 58 (36–60)
d 35 (30–50) 40 (20–43)
e ns
Coronary angiography
Normal 0 0 2 (33%) nd
1-vessel disease 9 (64%) 1 (20%) 1 (17%)
2-vessel disease 3 (21%) 2 (40%) 0
3-vessel disease 2 (14%) 2 (40%) 3 (50%)
Coronary intervention
LAD 9 (64%) 3 (60%) 1 (17%) nd
RCA 2 (14%) 1 (20%) 1 (17%)
CX 3 (21%) 1 (20%) 0
Hypothermic treatment 10 (71%) 4 (80%) 5 (83%) nd
Implantation of ICD 0 0 6 (100%) nd
Death prior to discharge 2 (14%) 2 (40%) 0 nd
Previous history
Angina pectoris 3 (21%) 0 1 (17%) nd
Myocardial infarction 0 5 (100%) 5 (83%)
Heart failure 0 1 (20%) 5 (83%)
a
Previous CABG 0 1 (20%) 2 (33%)
Previous PTCA 0 3 (60%) 2 (33%)
Hypertension 4 (29%) 2 (40%) 4 (67%)
Aortic stenosis 0 0 0
Mitral insufﬁciency 0 2 (40%) 4 (67%)
Diabetes mellitus 0 0 0
Hypercholesterolemia 10 (71%) 3 (60%) 2 (33%)




Family history 7 (70%)
f 2 (50%)
c 4 (67%)
Medication prior to admission
Beta-blocker 1 (7%) 1 (25%)
c 3 (50%) nd
Ca-blocker 1 (7%) 1 (25%)
c 2 (33%)
ACE/AT II-inhibitor 1 (7%) 2 (50%)
c 6 (100%)
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123results from an experimental study in rats by Shearer et al.
[7]. Kark et al. [10] sampled 20 MI-patients up to 7 days
after the event. Decreasing values of EPA were evident
after 42 h, whereas DHA started to increase 7 h after
admission. In that study there were no statistical analyses
for composite indexes, but we would expect that increasing
values of DHA (the major contributor to the sum of
EPA ? DHA) would reﬂect an increasing omega-3 index
after the initial 7 h of admission, a ﬁnding not conﬁrmed in
our study. The observed decrease in EPA after 42 h could,
however, have been missed by our investigation, as our
mean time to last sample was 35.6 h following admission.
The time between onset of symptoms and ﬁrst blood
sample was similar in the two studies. In contrast to the
study of Kark et al., our STEMI patients were treated
invasively, but there is no indication that this difference in
the treatment strategy may inﬂuence the FA composition in
phospholipids.
Unique to our study is a separate evaluation of the effect
of SCA on FA composition in humans. The so-far existing
research has been performed on primates [3] and rats [11].
In the study by Siscovick et al. [3] RBC membrane levels
of EPA ? DHA (corresponding to our omega-3 index)
were altered only slightly (0.33%) from the pre-mortem to
the post-mortem state, suggesting a non-signiﬁcant effect
on these FA by the cardiac arrest itself. Jurand et al. [11]
injected rats with noradrenaline, but could not demonstrate









Diuretics 1 (7%) 0
c 6 (100%)








Baseline blood samples (median)
Hemoglobin (g/L) 14.7 (13.5–15.8) 14.0 (13.0–17.0) 13.3 (11.1 15.1) ns
Sodium (mmol/L) 140 (136–142) 143 (142–144) 138 (136–144) 0.045
Calcium (mmol/L) 4.0 (3.9–4.6) 4.0 (3.8–4.6) 3.5 (3.1–4.6) ns
Creatinine (lmol/L) 92 (80–115) 110 (89–118) 107 (81–154) ns
Total-cholesterol (mmol/L) 6.4 (4.8–6.9) 3.8 (3.6–4.1) 3.7 (2.9–5.1) 0.014
HDL-cholesterol (mmol/L) 1.4 (1.0–1.7) 1.3 (0.9–1.8) 1.4 (0.7–1.8) ns




Glucose (mmol/L) 15.1 (8.7–22.5)
b 12.0 (9.4 -18.9) 13.8 (8.1 14.9)
e ns
hsCRP (mg/L) 1.7 (1.1–3.1) 1.8 (1.1–2.9) 3.2 (2.3–28.3) ns
Number of ﬁsh meals
\1 9 per month 1 (11%)
b 00 n d
2–3 9 per month 4 (44%)
b 2 (100%)
i 3 (50%)
1 9 per week 2 (22%)
b 0 1 (17%)
2–3 9 per week 1 (11%)
b 0 2 (33%)





h 2 (33%) nd
Fish-oil capsules 1 (11%)
b 1 (33%)
h 1 (17%)
Omega-3 index at admission (mean ± SD, %) 4.59 ± 1.58 5.26 ± 1.59 7.15 ± 1.77 0.014
Categorical data are given as n (%). Median values of continuous data given with 25th and 75th percentiles in parentheses (interquartile range)
Nd no data, p values not available, too small groups to test for differences for categorical variables. ns not signiﬁcant
ACE angiotensin converting enzyme, ASA acetylsalicylic acid, AT II angiotensin II receptor, BMI body mass index, CABG coronary artery bypass
grafting, HDL high density lipoprotein, hsCRP high-sensitivity C-reactive protein, ICD implantable cardioverter deﬁbrillator, LAD left anterior
descending artery, RCA right coronary artery, CX circumﬂex, NSTEMI non-ST-elevation myocardial, PTCA percutaneous transluminal coronary
angioplasty, SCA sudden cardiac arrest, SD standard deviation, STEMI ST-elevation myocardial infarction, TnT troponin-T
a For one of the patients the diagnosis of dilated cardiomyopathy was ﬁrst established after admission and this information is therefore not
included in the baseline characteristics;
b n = 9;
c n = 4;
d n = 12;
e n = 5;
f n = 10;
g n = 13;
h n = 3;
i n = 2
156 Lipids (2011) 46:151–161
123in these animal studies, and is strengthened by similar
results obtained in SCA-patients both with and without an
AMI. Although the latter group only consisted of 6
patients, these subjects represent a population in which we
could evaluate the effect of the cardiac arrest itself without
any interference from an AMI. Also, there was no evidence
Table 2 Characteristics of
cases and controls
Categorical data given as n (%).
Median values of continuous





acid, AT II angiotensin II
receptor, BMI body mass index,
CABG coronary artery bypass









a n = 9;
b n = 183;
c n = 12;
d n = 178;
e n = 141;
f n = 139;
g n = 10;
h n = 175;
i n = 184;
j n = 13
Case-patients (n = 14) Control patients (n = 185) p value
Men 12 (86%) 134 (72%) ns
Women 2 (14%) 51 (28%)
Age (median, years) 52.5 (46.8–59.5) 64 (53.5–73.0) 0.003
BMI (mean ± SD, kg/m
2) 26.6 ± 3.9
a 25.9 ± 4.5 ns
ECG ﬁndings at admission
STEMI 11 (79%) 85 (46%)
b 0.026
NSTEMI 3 (21%) 98 (54%)
b
Infarct location
Anterior wall 10 (71%) 85 (45%) ns
Inferior wall 3 (21%) 64 (35%)
Lateral wall 1 (7%) 0
Unidentiﬁable 0 36 (20%)




1-vessel disease 9 (64%) 55 (39%)
e ns
2-vessel disease 3 (21%) 39 (28%)
e
3-vessel disease 2 (14%) 47 (33%)
e
Death prior to discharge 2 (14%) 1 (0.5%) 0.013
Previous history
Angina pectoris 3 (21%) 56 (30%) ns
Heart failure 0 12 (7%) ns
Previous CABG 0 6 (3%) ns
Previous PTCA 0 8 (4%) ns
Hypertension 4 (29%) 61 (33%) ns
Diabetes mellitus 0 21 (11%) ns
Hypercholesterolemia 10 (71%) 92 (50%) ns




Family history 7 (70%)
g 121 (69%)
h ns
Medication prior to admission
Beta-blocker 1 (7%) 31 (17%) ns
Ca-blocker 1 (7%) 22 (12%)
i ns
ACE/AT II-inhibitor 1 (7%) 32 (17%) ns
Diuretics 1 (7%) 17 (9%) ns
ASA 1 (7%) 32 (17%) ns
Warfarin 0 8 (4%) ns
Statin 2 (14%) 36 (20%) ns
Baseline blood samples (median)
Hemoglobin (g/dL) 14.7 (13.5–15.8) 14.1 (13.1–15.0) ns
Creatinine (lmol/L) 92 (80–115) 89 (75–98) ns
Total-cholesterol (mmol/L) 6.4 (4.8–6.9) 5.6 (5.0–6.2) ns
HDL-cholesterol (mmol/L) 1.4 (1.0–1.7) 1.2 (1.0–1.5) ns
Triglycerides (mmol/L) 2.2 (1.0–3.2)
j 1.4 (1.0–2.0) ns
Glucose (mmol/L) 15.1 (8.7–22.5)
a 6.5 (5.6–8.6)
b \0.001
hsCRP (mg/L) 1.7 (1.1–3.1) 4.4 (2.0–13.5)
b 0.002
Omega-3 index (mean ± SD, %) 4.59 ± 1.58 6.48 ± 2.20 0.002
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123of a decreased omega-3 index at admission in patients
given adrenaline prior to hospitalization (5.60%, n = 14)
as compared to those not receiving this medication (5.01%,
n = 11).
Our ﬁndings suggest that any sample obtained within the
ﬁrst 48 h after an event of cardiac arrest, is representative
of the total FA status, including the omega-3 index and
AA/EPA ratio, of the individual prior to the event. Proof of
that assumption would, however, require a measurement
just prior to the event, but that would hardly be achievable
in a clinical setting. The other option would be blood
samples obtained in advance in large prospective cohort
studies, but in those settings dietary changes may have
taken place between the time of sampling and the event. As
a second-best choice, our study was designed to harvest the
ﬁrst sample as close to the event as possible, based on the
assumption that it may take some time for the cellular
changes to appear. The ﬁrst sample taken at admission was
harvested at a mean time of only 1.3 h after the SCA event.
Furthermore, the mean time from symptom onset was 3.3 h
in AMI-patients with SCA as compared to 3.4 h in AMI-
patients without a cardiac arrest. A possible effect of the
cardiac arrest on the FA proﬁle, has been one of the main
objections to case–control studies demonstrating an
increased risk of SCD/SCA with low levels of n-3 FA
[3, 5]. However, these objections are not supported by our
present results.
We had previously demonstrated that a 1% increase of
the omega-3 index reﬂects a 48% reduction in risk of VF
during the ischemic phase of an AMI [5]. In the present
case–control study we have recruited a similar group of
SCA-patients with ﬁrst-time MI, with the use of the same
control subjects in both study settings. As in our previous
investigation, we found a large difference in the omega-3
index values between cases and controls at admission.
Furthermore, the logistic regression analysis conﬁrms an
inverse relation between the omega-3 index and risk of VF;
a 1% increase in this index reﬂecting a 58% reduced risk of
VF (95% CI: 25–76%). Even though EF and hsCRP con-
tributed to the risk of VF, the omega-3 index was the
strongest predictor. The omega-3 index also remained an
independent predictor of risk, but was slightly attenuated,
in the subgroup analyses of STEMI-patients and anterior
infarctions. Contrary to other investigations, both of our
studies have documented ventricular ﬁbrillation at the time
of resuscitation, supporting the proposed antiarrhythmic
mechanism of n-3 FA [21–23], especially in ischemia-
induced VF. Theoretically, the antiarrhythmic mechanism
of n-3 FA is based on an increase of the arrhythmic
threshold in the ischemic zone of the myocardium, due to
an indirect effect of the FA on sodium and calcium ion-
channels in the myocardial membrane [22, 24].
The group of SCA patients without the presence of an
AMI is highly different from the ﬁrst-time MI population.
Their high omega-3 index of 7.15% does not contradict the
above ﬁnding, as their VF is mainly considered to be a
result of myocardial scarring and heart failure. For
arrhythmias generated by such mechanisms, n-3 FA might
not be protective, as suggested by the discrepant results of
n-3 FA in ICD-patients [25, 26]. Also, chronically ill
patients may have changed their lifestyle according to an
assumed protection by n-3 FA, ingesting an increased
amount of ﬁsh and omega-3 supplements.
Limitations
Our evaluation of a time-dependent change in the FA
proﬁle following an event of SCA and/or AMI is limited by
the relative low number of patients in each category,
reducing our power to conﬁdently exclude a small change.
Statistically, power calculations are difﬁcult to perform
with repeated sampling, but the use of serial samples
without any detectable change in healthy individuals and in
different patient groups strengthen our conclusion. As our
patient populations had highly different omega-3 index
values, the present study furthermore supports the stability
of this analysis in patients with both high and low n-3 FA
levels.
The main objection to the present case-control study
might be the different time-periods for inclusion of cases
and controls. Whereas controls were participants in the
RACS-study [5], sampled between November 2002 and
September 2003, our new cases had their blood samples
taken between February 2007 and June 2009. Both studies
were, however, performed at Stavanger University Hospi-
tal, the only hospital available for the CAD and SCA
Fig. 1 Mean of the omega-3 index with 95% conﬁdence interval (CI)
at admission (time 1), after 8–12 h (time 2) and 24–48 h (time 3).
Values given for sudden cardiac arrest (SCA) patients with and
without an acute myocardial infarction (MI), MI-patients without
SCA and healthy subjects (normal). p values for variance of the
omega-3 index in each group derived from the ANOVA analysis with
time as the only within-subject factor at three levels
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123Table 3 Fatty acid proﬁles from red blood cells
Patient group At admission 8–12 h 24–48 h p
SCA without MI (n = 6)
Myristic acid (C14:0) 3.56 (2.12–5.01) 5.00 (2.21–7.80) 5.29 (3.39–7.20) 0.276
Palmitic acid (C16:0) 23.10 (21.55–24.66) 22.59 (20.48–24.69) 22.98 (21.44–24.52) 0.843
Stearic acid (C18:0) 21.01 (18.36–23.66) 20.14 (17.42–22.87) 20.43 (18.43–22.44) 0.660
Oleic acid (C18:1n-9) 15.68 (13.93–17.43) 15.69 (14.40–16.98) 15.11 (14.08–16.14) 0.544
Linoleic acid (C18:2n-6) 8.32 (6.34–10.31) 8.19 (6.38–9.99) 8.04 (6.44–9.63) 0.427
a-Linolenic acid (C18:3n-3) 0.10 (0.03–0.17) 0.08 (0.04–0.12) 0.08 (0.03–0.12) 0.560
AA (C20:4n-6) 12.03 (9.96–14.11) 12.07 (9.72–14.43) 12.14 (10.16–14.12) 0.980
EPA (C20:5n-3) 1.42 (0.78–2.07) 1.36 (0.64–2.08) 1.24 (0.47–2.01) 0.429
DPA (C22:5n-3) 2.35 (1.83–2.86) 2.34 (1.80–2.88) 2.26 (1.92–2.60) 0.876
DHA (C22:6n-3) 5.73 (4.41–7.05) 5.61 (4.25–6.97) 5.58 (3.93–7.23) 0.949
Total n-3 FA 7.15 (5.30–9.01) 6.97 (4.98–8.96) 6.82 (4.54–9.09) 0.866
n-6 FA/n-3 FA 2.62 (1.93–3.31) 2.68 (1.99–3.37) 2.82 (1.98–3.66) 0.669
SCA with MI (n = 18)
Myristic acid (C14:0) 4.27 (3.21–5.32) 4.90 (3.88–5.92) 4.98 (3.27–6.70) 0.569
Palmitic acid (C16:0) 24.28 (22.95–25.60) 24.44 (23.09–25.78) 25.01 (24.07–25.94) 0.356
Stearic acid (C18:0) 20.47 (19.32–21.61) 20.71 (19.79–21.64) 20.93 (20.05–21.82) 0.552
Oleic acid (C18:1n-9) 15.34 (14.43–16.25) 15.27 (14.59–15.96) 15.22 (14.38–16.06) 0.933
Linoleic acid (C18:2n-6) 9.55 (9.02–10.09) 9.37 (8.81–9.92) 9.27 (8.61–9.93) 0.144
a-Linolenic acid (C18:3n-3) 0.10 (0.08–0.12) 0.10 (0.07–0.13) 0.09 (0.06–0.11) 0.470
AA (C20:4n-6) 11.12 (9.87–12.37) 10.56 (9.49–11.63) 10.24 (9.49–10.99) 0.101
EPA (C20:5n-3) 0.79 (0.60–0.97) 0.70 (0.47–0.92) 0.74 (0.54–0.95) 0.283
DPA (C22:5n-3) 1.91 (1.67–2.15) 1.87 (1.61–2.12) 1.76 (1.51–2.01) 0.218
DHA (C22:6n-3) 3.91 (3.34–4.48) 3.80 (3.19–4.42) 3.68 (3.21–4.15) 0.591
Total n-3 FA 4.70 (4.03–5.37) 4.50 (3.72–5.28) 4.43 (3.82–5.03) 0.576
n-6 FA/n-3 FA 3.95 (3.48–4.42) 4.00 (3.45-4.56) 4.04 (3.46–4.62) 0.891
MI without SCA (n = 15)
Myristic acid (C14:0) 5.91 (4.59–7.23) 6.33 (4.92–7.74) 7.13 (5.61–8.66) 0.380
Palmitic acid (C16:0) 25.79 (24.90–26.67) 25.40 (24.59–26.22) 24.99 (24.23–25.75) 0.135
Stearic acid (C18:0) 21.79 (21.03–22.54) 21.42 (20.76–22.09) 21.18 (20.41–21.95) 0.214
Oleic acid (C18:1n-9) 14.82 (14.11–15.54) 14.61 (13.98–15.23) 14.43 (13.81–15.06) 0.499
Linoleic acid (C18:2n-6) 9.22 (8.32–10.11) 9.20 (8.32–10.08) 8.82 (8.00–9.64) 0.053
a-Linolenic acid (C18:3n-3) 0.12 (0.09–0.15) 0.15 (0.10–0.20) 0.16 (0.10–0.23) 0.335
AA (C20:4n-6) 8.23 (7.40–9.06) 8.46 (7.65–9.27) 8.52 (7.54–9.49) 0.616
EPA (C20:5n-3) 0.68 (0.44–0.92) 0.69 (0.43–0.95) 0.63 (0.43–0.84) 0.361
DPA (C22:5n-3) 1.65 (1.47–1.84) 1.66 (1.51–1.80) 1.69 (1.57–1.82) 0.804
DHA (C22:6n-3) 3.18 (2.55–3.80) 3.36 (2.69–4.03) 3.34 (2.71–3.98) 0.421
Total n-3 FA 3.85 (3.03–4.67) 4.05 (3.18–4.92) 3.98 (3.18–4.77) 0.562
n-6 FA/n-3 FA 4.09 (3.35–4.83) 4.03 (3.21–4.85) 3.88 (3.21–4.56) 0.239
Healthy subjects (n = 5)
Myristic acid (C14:0) 7.00 (2.87–11.13) 5.18 (1.64–8.71) 4.45 (2.88–6.02) 0.207
Palmitic acid (C16:0) 23.90 (21.87–25.93) 23.47 (22.48–24.46) 23.73 (22.25–25.20) 0.904
Stearic acid (C18:0) 21.09 (18.69–23.49) 20.88 (20.03–21.72) 21.06 (20.06–22.06) 0.956
Oleic acid (C18:1n-9) 13.86 (12.63–15.08) 15.34 (13.08–15.59) 14.70 (13.72–15.69) 0.232
Linoleic acid (C18:2n-6) 9.74 (8.58–10.91) 10.27 (8.74–11.81) 10.14 (9.08–11.21) 0.312
a-Linolenic acid (C18:3n-3) 0.17 (0.01–0.33) 0.12 (0.08–0.15) 0.13 (0.09–0.17) 0.613
AA (C20:4n-6) 9.04 (7.23–10.85) 9.99 (8.12–11.86) 9.98 (7.85–12.11) 0.409
EPA (C20:5n-3) 1.53 (0.53–2.53) 1.73 (0.87–2.59) 1.69 (0.79–2.59) 0.393
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123populations in this region of Norway. The source-popula-
tion should therefore be similar for both studies and there is
no reason to believe that their way of living, including diet,
would have changed signiﬁcantly during a 5 year period.
The results of our study are, however, only valid for the
range of omega-3 index values included in the analyses.
Furthermore, we do not know for certain whether the
omega-3 index in admitted SCA-patients differ from those
of OHCA-patients where ROSC was not obtained. Also,
the urgent situation during resuscitation and admission
sometimes resulted in missing samples for admitted SCA-
patients.
Conclusion
Our study supports an association between low levels of
n-3 FA and the risk of VF during the ischemic phase of an
AMI in hospitalized patients. The results are strengthened
by our demonstration of the stability of RBC FA within the
ﬁrst 48 h after an episode of SCA or AMI, suggesting that
the validity of risk assessment is maintained within this
time frame.
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